Skip to content
lifestyle.pluralist.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
ELI LILLY AND COMPANY
FDA approves Lilly’s Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes
August 28, 2026
Zepbound linked to lower healthcare costs in adults over age 55 with obesity according to a real-world study
August 26, 2026
Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market
August 12, 2026
Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress
August 5, 2026
Lilly’s olomorasib receives U.S. FDA’s Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancer
August 3, 2026
Lilly’s triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C
July 23, 2026
Lilly confirms date and conference call for second-quarter 2026 financial results announcement
July 22, 2026
Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions
July 16, 2026
/C O R R E C T I O N — Eli Lilly and Company/
July 9, 2026
Lilly to present Alzheimer’s disease diagnostic and therapeutic research at AAIC 2026, including new data on P-tau217 blood tests and amyloid-targeting treatment
July 9, 2026
←
Previous Page
1
2
3
4
…
6
Next Page
→